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Abstract
Overexpression of neurotensin receptors (NTRs) has been suggested to play important roles in the 
growth and survival of a variety of tumor types. The aim of this study is to develop a dual-
modality probe (64Cu -DOTA-NT-Cy5.5) for imaging NTR1 expression in vivo with both positron 
emission tomography (PET) and fluorescence. In this approach, the thiol group and N terminal 
amino group of neurotensin analogue (Cys-NT) were chemically modified with Cy5.5 dye and 
DOTA chelator, respectively. After radiolabeling with 64Cu, the resulting probe (64Cu-DOTA-NT-
Cy5.5) was evaluated in NTR1 positive HT-29 tumor model. Small animal PET quantification 
analysis demonstrated that the tumor uptake was 1.91 ± 0.22 and 1.79 ± 0.16%ID/g at 1 and 4 h 
postinjection (p.i.), respectively. The tumor-to-muscle ratio was 17.44 ± 3.25 at 4 h p.i. based on 
biodistribution. Receptor specificity was confirmed by the successful blocking experiment at 4 h 
p.i. (0.42 ± 0.05%ID/g). In parallel with PET experiment, fluorescence imaging was also 
performed, which demonstrated prominent tumor uptake in HT-29 model. As a proof of concept, 
an imaging guided surgery was performed to the fluorescent moiety of this probe and could 
provide potential surgery guidance for NTR positive patients. In summary, our results clearly 
indicated that the dual-modality probe, 64Cu-DOTA-NT-Cy5.5, could serve as a promising agent 
to image NTR positive tumors in vivo.
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Introduction
Multimodality imaging is a fast growing research area involving the integration of different 
imaging modalities together. As each imaging modality has its own advantages and 
weaknesses, the combination of two or more imaging modalities may lead to a 
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complementary imaging approach that would not present the shortfalls of the individual 
modalities.1–6 In particular, PET can provide critical in vivo information on the distribution 
of radiolabeled biomolecules with potential applications in noninvasive cancer diagnosis; 
and fluorescence (FL) imaging has been demonstrated to have superior sensitivity for 
intraoperative tumor detection (invasive surgery) when compared to conventional visual 
inspection.4,7–9 Clearly, PET/FL dual modality imaging could become an attractive strategy 
for patient management.
The G-protein-coupled neurotensin receptor (NTR) represents a very important cancer 
related target, as it is overexpressed in a variety of tumors, especially prostate cancer, 
colorectal cancer, pancreatic cancer, breast cancer, and lung cancer.10–13 Indeed, recent 
studies showed that NTRs influence the signaling on IL-8 expression and subsequent 
CXCR1/STAT3 signaling pathway activation in malignant tumors and induce gelsolin-
mediated invasion of cancer cell through NTR1 activation.14,15 In addition, NTR1 shows 
negligible or low expression in healthy tissues, which makes it a very promising specific 
molecular target for imaging and targeted cancer therapy.16 Neurotensin (NT) is a 
tridecapeptide ligand (pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Try-Ile-Leu), which 
can be readily modified for pharmacokinetics optimization and for radiolabeling with 
various imaging isotopes. Several radio-labeled NT analogues were recently developed as a 
valuable tool for both imaging and therapy of NTR-positive tumors.17–23 Our research has 
been focused on the NTR-targeted probes development. Previously we synthesized and 
evaluated the thiolated neurotensin peptide being labeled with 18F-DEG-VS, which 
demonstrated great potential for the detection of NTR positive tumors by PET imaging.24
In this report, we aim to develop a NTR targeted PET/optical dual-modality imaging probe 
that could become an attractive agent for patient management: PET will provide critical in 
vivo information on the NTR expression in vivo and fluorescence imaging will facilitate 
intraoperative tumor detection (invasive surgery).25 Because the Cys-NT bears both N 
terminal amino group and thiol functional group, fluorescent dye and radiometal chelator 
could be introduced to the peptide selectively. The resulting probe is further evaluated by 
PET and fluorescence imaging in a rodent model with NTR1-positive HT-29 tumor.
Materials and Methods
General
All chemicals and solvents were obtained from commercial sources and used without further 
purification. Sulfo-N-hydroxysulfosuccinimide (Sulfo-NHS) and ethyl-
(dimethylaminopropyl) carbodiimide (EDC) were purchased from Sigma-Aldrich. 1,4,7,10-
Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was obtained from Macrocyclics, 
Inc. Cy5.5-Mal was purchased from GE healthcare.
Synthesis of NT-Cy5.5
Thiolated Cys-NT (0.25 μmol) was dissolved in 300 μL of H2O and added to 0.29 μmol of 
Cy5.5-Mal in 30 μL of dimethyl sulfoxide (DMSO) (final pH 7.0). The reaction was 
incubated at room temperature (RT) for 30 min. HPLC purification afforded the final 
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product as blue solid. The retention time of NT-Cy5.5 on analytical HPLC is 18.64 min. The 
product was confirmed by Q-TOF LC/MS, m/z is 2221.89, C102H143N20O26S5; calculated 
[MH]+, 2221.89).
Synthesis of DOTA-NT-Cy5.5
Activated DOTA (2 μmol) was prepared based on literature report. Without purification, 
DOTA-sNHS solution was added to NT-Cy5.5 (0.16 μmol) in 40 μL of borate buffer (pH 
8.5). The reaction stayed at RT for 30 min. HPLC purification afforded the final product as 
blue solid after lyophilization. The retention time of DOTA-NT-Cy5.5 on analytical HPLC is 
18.55 min. The product was confirmed by Q-TOF LC/MS, m/z is 2607.95 for [MH]+, 
C118H165N24O33S5, calculated [MH]+, 2608.07).
Radiochemistry
DOTA-NT-Cy5.5 was labeled with 64CuCl2 in ammonium acetate buffer (pH 5.5). The 
reaction mixture was kept at 37 °C for 60 min. Analytical HPLC was used to purify 
the 64Cu-labeled peptide. The radioactive peak containing the desired product was collected 
and rotavaped to remove organic solvent. After adjusting the pH, the imaging probe was 
reconstituted in 1 mL 1×PBS for in vivo animal experiments.
In Vitro Stability
64Cu-DOTA-NT-Cy5.5 was purified by HPLC. The peak containing 64Cu-DOTA-NT-Cy5.5 
was collected, and the solvent was removed by rotavap. The HPLC purified product was 
then reconstructed in PBS (1×) to 37 MBq/mL and analyzed by radio-HPLC at 30 min, 2 h, 
and 6 h after incubation.
Cells and Animals
The human colon adenocarcinoma cell HT-29 was obtained from the Tissue Culture Facility 
of UNC Lineberger Comprehensive Cancer Center. In brief, the cells were cultured in 
McCoy's 5A medium with 10% fetal bovine serum (FBS) in a humidified atmosphere of 5% 
CO2 at 37 °C. The cells were expanded in tissue culture dishes every other day, and the 
medium was changed at the same time. When grown to 80% confluence, the cells were 
detached with 0.05% trypsin-ethylenediaminetetraacetic acid (EDTA) for cell binding assay 
or animal tumor injection. Animal procedures were performed according to a protocol 
approved by the University of North Carolina Institutional Animal Care and Use Committee. 
In the procedure, 4- to 6-wk-old male athymic mice (BALB/c nu/nu; weight, 20–30 g) were 
injected subcutaneously with HT-29 human colon adenocarcinoma cells at a concentration 
of 1 × 106 cells per 0.1 mL in the shoulder, and enough time was allowed for tumors to grow 
to at least 3 mm in diameter.
In Vitro Cell Binding Assay
The in vitro NTR1-binding affinity and specificity of DOTA-NT-Cy5.5 and Cys-NT were 
assessed via competitive cell binding assays using 125I-NT(8-13) (Phoenix Pharmaceuticals, 
Inc.) as the NTR1 specific radio-ligand based on previous report.24,26 The best-fit 50% 
inhibitory concentration (IC50) values for HT-29 cells were calculated by fitting the data 
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with nonlinear regression using GraphPad Prism (GraphPad Software). Experiments were 
performed on triplicate samples.
Small Animal PET Imaging
Animal procedures were performed according to a protocol approved by the University of 
North Carolina Institutional Animal Care and Use Committee. In brief, each mouse bearing 
HT-29 xenograft was injected with approximately 3.7 MBq of 64Cu-DOTA-NT-Cy5.5 via 
the tail vein (n = 3/group). The same amount of activity was injected into the blocking group 
with unlabeled NT (100 μg) through the tail vein. The imaging data were achieved at 1 and 4 
h p.i. using a small animal PET scanner (GE eXplore Vista), with the mice under anesthesia 
using isoflurane (3% for induction and 2% for maintenance). The regions of interest (ROIs) 
were converted to counts per gram per minute based on the assumption of 1 g/mL tissue 
density. Dividing counts per gram per minute by injected dose gave the image ROI-derived 
percentage injected dose per gram tissue (%ID/g) values.
Biodistributions were performed in nude mice bearing HT-29 tumor. Animals were 
sacrificed under inhalation anesthesia at 4 h postinjection of 3.7 MBq of 64Cu-DOTA-NT-
Cy5.5. Tissues and organs of interest were excised and weighed. Radioactivity in each 
excised specimen was measured using a γ-counter (PerkinElmer). The mean uptake (%ID/g) 
was calculated for each group of animals.
In Vivo and ex Vivo Near-Infrared Fluorescence Imaging
In vivo fluorescence imaging was performed using the FMT 2500 imaging system (VisEn, 
Inc.) and analyzed using the IVIS Living Imaging 3.0 software (Caliper Life Sciences, 
Alameda, CA, USA). A Cy5.5 filter set was used for acquiring the fluorescence of Cy5.5 
dye conjugated to DOTA-NT peptide. Identical illumination settings (lamp voltage, filters, f/
stop, field of views, binning) were used for acquiring all images. Fluorescence emission 
images were normalized and reported as photons per second per centimeter squared per 
steradian (p/s/cm2/sr). The mice received 1.5 nmol of 64Cu-DOTA-NT-Cy5.5 peptide 
intravenously and subjected to optical imaging at 1 and 4 h p.i. For blocking studies, the 
probe was coinjected into mice with 100 μg of NT peptide. The tumors, tissues, and organs 
were dissected and subjected to ex vivo fluorescence imaging at 4 h p.i. All fluorescence 
images were acquired using 1 s exposure time (f/stop = 4). The mean fluorescence for each 
sample was reported.
Immunohistochemistry and Microscopy
The DOTA-NT-Cy5.5 was injected intravenously into HT-29 mouse model without and with 
a blocking dose of NT peptide. Tumors were isolated at 4 h p.i. and embedded with Paraffin, 
which were then sectioned in 6 μm thickness using cryostat at −25 °C and fixed in ice-cold 
acetone for 15 min. After washing with PBS, endogenous peroxidase was neutralized by 
methanol solution containing 3% (v/v) H2O2. The section was washed and blocked with 
10% normal horse serum (Vector Laboratories, Inc.) for 1 h at RT. Vasculature was stained 
using CD31 antibody (Santa Cruz Biotechnology). After washing three times with PBS, 
detection of CD31 primary antibody was performed using a 1:200 dilution of mouse FITF-
labeled secondary antibody (Vector Laboratories, Burlingame, CA). The samples were 
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washed with PBS three times, and then stained with 2 μg/mL of 4,6-diamidino-2-
phenylindole (DAPI) for 20 min at 37 °C. Each slide was occluded with 50% glycerin buffer 
and was observed using a confocal laser scanning microscope (Olympus, Tokyo, Japan) 
equipped with a 40× objective lens.
Data Analysis
Quantitative data are expressed as mean ± SD. Means were compared using one-way 




The synthesis of DOTA-NT-Cy5.5 is shown in Scheme 1. In the first step, NT was 
conjugated with Cy5.5-Mal to afford NT-Cy5.5 in 90% yield after HPLC purification. In the 
second step, the free carboxyl group on DOTA was activated with EDC/Sulfo-NHS and then 
reacted with NT-Cy5.5 at pH 8.5. The DOTA-NT-Cy5.5 was labeled with 64Cu efficiently in 
0.1 M NH4OAc buffer within 60 min at 37 °C. The specific activity of 64Cu-DOTA-NT-
Cy5.5 was about 10.2 GBq/μmol. The radiochemical purity of 64Cu-DOTA-NT-Cy5.5 was 
greater than 98.9%, 96.9%, and 90.8% at 30 min, 2 h, and 6 h after incubation in phosphate-
buffered saline, respectively (Figure 1).
In Vitro Cell-Binding Affinity
The receptor-binding affinity of DOTA-NT-Cy5.5 was compared with that of Cys-NT using 
a competitive cell-binding assay (Figure 2). Both peptides inhibited the binding of 125I-
NT(8–13) to NTR1-positive HT-29 cells in a dose-dependent manner. The IC50 (the half 
maximal inhibitory concentration) value for DOTA-NT-Cy5.5 (0.65 ± 0.35 nmol/L) was 
comparable to that of Cys-NT (0.43 ± 0.15 nmol/L). The results clearly demonstrated that 
the modification has minimal effect on NTR binding affinity of DOTA-NT-Cy5.5.
Biodistribution and Small Animal PET Imaging
The in vivo tumor-targeting property of 64Cu-DOTA-NT-Cy5.5 was evaluated in HT-29 
xenografts (NTR1-positive) at 1 and 4 h p.i. with static PET scans. As shown in Figure 3A, 
the HT-29 tumors were clearly visualized with high tumor-to-background contrast. ROI 
analysis on PET images shows that the tumor uptake was 1.91 ± 0.22 and 1.79 ± 0.16%ID/g 
at 1 and 4 h p.i., respectively (Figure 3C). The NTR1-targeting specificity of 64Cu-DOTA-
NT-Cy5.5 was further confirmed by the effective blocking of HT-29 tumor uptake in the 
presence of 100 μg of unlabeled NT peptide (Figure 3B). For example, the tumor uptake was 
decreased from 1.79 ± 0.16%ID/g to 0.42 ± 0.05% ID/g (blocked) at 4 h p.i. (P < 0.05). 
There was no significant difference in most of the normal organs (e.g., liver, kidneys, and 
muscle) between these two groups. As shown in Figure 4, in order to confirm PET result, 
biodistribution was also performed. The biodistribution result was consistent with the PET 
images. The kidney had the highest uptake of 64Cu-DOTA-NT-Cy5.5 with 14.24 
± 1.33%ID/g, next to the liver with 4.63 ± 0.74%ID/g at 4 h p.i. The muscle, lung, and heart 
Deng et al. Page 5













had relatively low uptake of 64Cu-DOTA-NT-Cy5.5 (Figure 4). The tumor-to-muscle ratio 
was 17.44 ± 3.25 at 4 h p.i.
Fluorescent Imaging
The optical imaging ability of 64Cu-DOTA-NT-Cy5.5 was evaluated with the fluorescence 
imaging system immediately after each PET scan. Similar to PET images, the HT-29 tumor 
lit up at all the time points examined (Figure 3D). Ex vivo images of 64Cu-DOTA-NT-Cy5.5 
were used to confirm the in vivo fluorescence imaging data (4 h p.i.). As shown in Figure 5, 
both PET and fluorescence gave good tumor to muscle contrast. The tumor, liver, and 
kidneys are three motifs that showed high probe uptake. Brain and other major organs have 
comparable background signal due to autofluorescence. Overall, the biodistribution profiles 
of fluorescent imaging showed similar patterns with those of PET. It worth pointing out we 
do observe discrepancy on tumor to liver ratio between PET and optical imaging. Based on 
PET imaging and biodistribution, HT-29 tumor has lower uptake than liver. However, optical 
imaging showed higher tumor uptake than liver. Whether this phenomena is caused by the 
blood in liver or the stability of the tracer needs to be further investigated in follow up 
studies.
Image-Guided Surgery
BALB/c nude mice with HT-29 were imaged by fluorescence imaging at 4 h postinjection of 
radiolabeled 64Cu-DOTA-NT-Cy5.5. After preoperative evaluation of tumor lesions by PET, 
image-guided surgery of the tumor lesions was performed. First, the exact tumor location 
was identified by fluorescence imaging. Subsequently, these tumor lesions were resected, 
and fluorescence imaging was repeated to ensure complete resection of the tumor. In Figure 
6, the feasibility of using the probe for intraoperative image-guided surgical resection of the 
tumor nodules is shown.
Immunohistochemistry and Microscopy
Representative images of HT-29 xenograft tumor sections isolated from animals after 
injection of DOTA-NT-Cy5.5 with and without a blocking dose of NT peptide are shown in 
Figure 7. Analysis of tumors from blocking animals showed very weak fluorescent signals 
compared to DOTA-NT-Cy5.5. The results clearly demonstrated the specific binding of 
DOTA-NT-Cy5.5 in HT-29 tumor using FL microscope (tumor localization was clearly 
inhibited by coinjected Cys-NT peptide).
Discussion
Molecular imaging is an emerging technology that can visualize the interactions between 
molecular probes and biological targets. In recent years, tremendous progress has been made 
to develop novel molecular imaging probes and techniques to characterize mechanisms 
involved in a pathologic process. Among the technologies, PET is a powerful molecular 
imaging technique that is used to study and visualize the metabolism, receptor/enzyme 
function, and biochemical mechanisms in vivo.27 Fluorescence imaging with fluorophores 
conjugated to tumor-targeting agents can provide sensitive intraoperative detection as a 
visual guide, despite its in vivo application by the light penetration. In recent years, the 
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combination of fluorescence and PET imaging is rapidly emerging as a new sensitive 
molecular imaging technology, which could provide an attractive strategy for tumor patient 
management.28–30 With this dual-modality approach, the tumor could be assessed 
preoperatively, with subsequent intraoperative guidance for surgical removal of the tumor 
lesions based on the fluorescent component of the dual-label agent.29,31,32 In oncology, 
molecular imaging is mainly dependent on the availability of a specific target on tumor cells 
or within the tumor stroma or vasculature, and the quality of the designed labeled probe, 
which depends on its biodistribution, metabolism, affinity, and specificity for the target. 
Among the targets, NTR1 is one of the very promising targeting receptors. Accumulating 
evidence suggests that NTR1 play key roles in cancer growth and survival.16,33,34 NT, a 
tridecapeptide ligand for NTR, acts as a mediator in tumor progression and is metabolized 
rapidly in plasma by endogenous peptidases. Several NT analogues have been developed and 
radiolabeled as a valuable tool for both imaging and therapy of NTR-positive 
tumors.17–22,24,35 Although some encouraging results have been achieved in these initial 
studies, to our best knowledge, there is no report on peptide based NTR1 targeted 
multimodality imaging agent.
In this study, we developed a dual-modality PET and fluorescent imaging probe, 64Cu-
DOTA-NT-Cy5.5, which has been well established to have high NTR1 expression, and 
evaluated it in HT-29 tumor-bearing mice.36 Because the chemical modification of a peptide 
could also significantly decrease receptor binding affinity, an in vitro cell-binding assay of 
DOTA-NT-Cy5.5 and NT was performed. The binding affinities of DOTA-NT-Cy5.5 and NT 
were not significantly different (Figure 2), as supported by the similar IC50 values.
The probe has good stability in vitro, with the radiochemical purity of more than 98.9%, 
96.9%, and 90.8% at 30 min, 2 h, and 6 h after incubation in phosphate-buffered saline, 
respectively. Despite the reasonable in vitro stability, further improvement on the stability of 
NT analogues (especially in vivo stability) is warranted in future follow-up studies. Both 
PET and fluorescent images showed high and specific accumulation of the dual-labeled Cys-
NT in the NTR1 expressing tumor lesions. The high and specific accumulation of 64Cu-
DOTA-NT-Cy5.5 in the NTR1-expressing tumor lesions was confirmed by blocking 
experiments (Figures 3, 5, and 7). In the blocking experiment, nonradioactive Cys-NT 
peptide significantly (P < 0.05) inhibited the tumor uptake of 64Cu-DOTA-NT-Cy5.5 
(Figures 3 and 5) at all time points, clearly demonstrating the receptor specificity of this 
imaging agent.
We also performed a biodistribution study to determine the uptake in liver, kidney, small 
intestine, spleen, heart, and other organs or tissues more accurately. As shown in Figure 4, 
the uptake in these organs was correlating well with that in PET imaging (Figure 3). 64Cu-
DOTA-NT-Cy5.5 could be cleared through renal pathway, which also leads to predominant 
accumulation in the kidneys. The liver also has high uptake of 64Cu-DOTA-NT-Cy5.5, 
which is different from our previous study.24 It is possible that the probe becomes more 
hydrophobic after introducing the Cy5.5 dye, which makes it also be cleared by the liver. A 
high tumor-to-muscle ratio (17.44 ± 3.25) was obtained at 4 h p.i., calculated by 
biodistribution study, which indicates that 64Cu-DOTA-NT-Cy5.5 is a promising dual-
modality PET tracer for imaging of NTR-1 expressing tumors. Although high binding 
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affinity was observed in vitro (IC50 value of 0.65 ± 0.35 nmol/L), the NTR targeted PET 
agent demonstrated moderate HT-29 tumor uptake in vivo (1.91 ± 0.22 and 1.79 
± 0.16%ID/g at 1 and 4 h p.i., respectively). The tumor uptake was determined not only by 
probe's target binding affinity but also by many other factors including circulation time, 
water solubility, stability, etc. Clearly, systematic investigation is needed to further improve 
the absolute tumor take in follow-up studies.
As shown in Figure 3, the tumor could be clearly located by PET scans and optical imaging, 
and the biodistribution pattern is consistent between these two imaging modalities except 
liver. Liver showed higher uptake in PET images than fluorescence images. There are two 
possible reasons: (1) Liver is a relatively large organ and rich of blood. Due to the limited 
tissue penetration capability of fluorescence signal and high absorption of blood, the liver 
uptake may be underestimated on optical imaging. (2) 64Cu-DOTA-NT-Cy5.5 may release 
free 64Cu in vivo, which could cause the higher liver uptake in PET images. In our study, we 
have observed good probe stability in PBS up to 6 h postincubation, which lessens the 
stability concern to some extent. However, additional investigation is needed before a 
conclusion is drawn.
In order to demonstrate the advantage of introducing fluorescence into our probe, a proof of 
principle imaging guided surgery is performed. The tumor was successfully identified using 
fluorescent imaging and removed under the fluorescence imaging guidance (Figure 6). The 
accumulation of the probe could also be observed using fluorescent microscope (Figure 7). 
Blocking experiment successfully reduced the localization of 64Cu-DOTA-NT-Cy5.5 within 
tumor region due to the presence of excess amount of cold NT analogues. Comparable 
CD31 staining was observed in both groups. This preliminary study clearly demonstrates 
that pre- and intra-operative detection of NTR1-expressing lesions might be feasible with the 
newly developed PET/optical dual-modality imaging.
Conclusion
By chemical modification of Cys-NT peptide with Cy5.5 dye and DOTA chelator, we have 
successfully synthesized and evaluated a novel dual-modality PET/fluorescence imaging 
probe, 64Cu-DOTA-NT-Cy5.5, as a NTR1-targeted imaging agent. Both PET and 
fluorescence images clearly showed specific tumor uptake and good tumor-to-background 
contrast. Overall, good concordance was observed between the two imaging modalities 
except liver. This PET/optical tumor-targeting probe not only allows the detection of NTR-1 
expressing tumors by PET imaging but also integrates PET with image-guided surgery.
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HPLC profiles of 64Cu-DOTA-NT-Cy5.5 at 30 min, 2 h, and 6 h after purification with 
radiochemical purity more than 98.9%, 96.9%, and 90.8%, respectively.
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Competitive cell binding assays of 125I-NT(8–13) and DOTA-NT-Cy5.5 or Cys-NT in 
HT-29 cells. X-axis stands for the concentration of nonradiolabeled competitor. IC50 values 
for DOTA-NT-Cy5.5 and Cys-NT were 0.65 ± 0.35 and 0.43 ± 0.15 nmol/L, respectively.
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PET/CT images of HT-29 tumor-bearing mice at 1 and 4 h postinjection of 64Cu-DOTA-NT-
Cy5.5 (A) without and (B) with a blocking dose of NT peptide. (C) The quantitative tumor 
and muscle uptakes derived from PET images. (D) In vivo fluorescent images of HT-29 
tumor-bearing mice.
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Biodistribution of 64Cu-DOTA-NT-Cy5.5 in mice bearing HT-29 xenograft at 4 h p.i.
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Ex vivo fluorescent images of major organs harvested at 4 h p.i. of 64Cu-DOTA-NT-Cy5.5 
(A) without and (B) with coinjection of Cys-NT.
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Athymic female nude mouse bearing HT-29 tumor at 4 h postinjection of 64Cu-DOTA-NT-
Cy5.5. The tumor lesion was subsequently removed by fluorescent image-guided surgery. 
(A–D) Digital pictures of the mouse and the tumors during surgery. (E–H) Fluorescent 
images as a visual guide during surgery.
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In vivo functional targeting of the novel DOTA-NT-Cy5.5. Representative serial sections of 
HT-29 xenograft tumors stained with DAPI (blue), CD31 antibody (green), and DOTA-NT-
Cy5.5 (red).
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Scheme 1. Synthesis of 64Cu-DOTA-NT-Cy5.5a
aReagents and conditions: a. pH 7.5, 30 min RT. b. EDC/SNHS, pH = 5.5. c. borate buffer 
(pH 8.5), 30 min RT. d. NH4OAc (pH 5.5), 37 °C, 60 min.
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